Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
30/433 Publications
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
-
Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
-
Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
-
Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
-
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
-
The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
-
Noninvasive evaluation of NAFLD.
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
-
[The prevalence of liver and gallbladder pathologies in overweight and obese patients].
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
-
Fibroscan and FibroTest/FibroMax to assess liver fibrosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia.
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
FibroMAX: towards a new universal biomarker of liver disease?
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
Showing the full result list. The page is server-rendered and not paginated.